newsfilter
← Latest News
Business Wire·

Prothena Announces up to $100 Million Share Repurchase Plan

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of